港股異動丨兆科眼科(6622.HK)漲逾5% 環孢素A眼凝膠關鍵第III期臨牀試驗(COSMO)達到預設主要研究終點
格隆匯8月18日丨兆科眼科(6622.HK)漲逾5%,暫錄三連漲,報8.51港元,總市值46億港元。兆科眼科公吿稱,環孢素A眼凝膠關鍵第III期臨牀試驗驗(COSMO)顯示該研究的下角膜螢光素染色法分數(ICSS)達到預設主要研究終點。公司目標仍為於2021年底前向國家藥品監督管理局(藥監局)提交新藥申請。環孢素A眼凝膠是本公司於中國開發以供治療乾眼症的創新環孢素凝膠。有別於Restasis乳液配方,環孢素A眼凝膠是專利水凝膠,其專利權已於中國以至國際範圍獲批。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.